文献速递脊柱关节炎

真实世界银屑病关节炎患者达标治疗:bDMARDs/tsDMARDs实现最低疾病活动度及潜在障碍

Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs/tsDMARDs and potential barriers.
PubMed 文献 · Semin Arthritis Rheum · 2023-07-04

该研究纳入104例稳定使用bDMARDs/tsDMARDs的银屑病关节炎患者,每6个月评估直至36个月,纵向探索MDA预测因素。52%为中轴型PsA,各次评估中52-61%达到MDA,17-24%达到ASDAS-LDA;中轴型PsA、纤维肌痛、骨关节炎和BMI≥35与持续MDA负相关。

要点

  • 真实世界中52-61%的PsA患者可达MDA,17-24%的中轴型患者可达ASDAS-LDA
  • 中轴型PsA、纤维肌痛、骨关节炎和BMI≥35是MDA的独立负相关因素
  • 纤维肌痛和骨关节炎亦与ASDAS-LDA独立负相关,中轴型PsA为难以治疗亚组

核心结论

  • MDA在真实世界中是可达到的治疗目标,但中轴型PsA代表难以治疗的亚组。
  • 持续MDA取决于疾病特征(中轴型PsA)以及患者特征(如年龄、bDMARDs/tsDMARDs使用时长、合并症)。

研究设计与样本

  • 连续纳入本中心稳定使用bDMARDs/tsDMARDs的银屑病关节炎患者,基线及每6个月评估疾病活动度指标,随访至36个月或停药。
  • 共纳入104例患者,男性54%,平均年龄55.7岁,52%为中轴型PsA。
  • 采用多变量广义估计方程(GEE)模型识别MDA和ASDAS-LDA的预测因素,数据以beta系数(95%CI)表示。

主要发现

  • 所有评估中52-61%的患者达到MDA,17-24%达到ASDAS-LDA。
  • GEE模型显示与MDA显著独立相关的因素:年龄(Beta=-0.05)、bDMARDs/tsDMARDs使用时长(Beta=+0.31)、中轴型PsA(Beta=-1.07)、纤维肌痛(Beta=-3.35)、骨关节炎(Beta=-1.87)、BMI≥35(Beta=-2.53)。
  • 年龄(Beta=-0.01)、纤维肌痛(Beta=-2.03)和骨关节炎(Beta=-1.30)亦与ASDAS-LDA独立相关。

关键数值与推荐

  • MDA评估采用最低疾病活动度标准。
  • 中轴型PsA患者采用ASDAS-LDA评估。
  • 持续MDA组中中轴型PsA、纤维肌痛、骨关节炎和BMI≥35较少见。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: (1) to describe the frequency of minimal disease activity (MDA) in a real-life psoriatic arthritis (PsA) cohort, (2) to longitudinally explore predictors of MDA; (3) to examine frequency and predictors of low disease activity (LDA) in patients with axial involvement (axPsA). METHODS: consecutive PsA patients in stable biological/targeted-synthetic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs/tDMARDs) who attended our center were enrolled. Disease activity indices, including MDA and ankylosing spondylitis disease activity score-LDA (ASDAS-LDA) for axPsA, were evaluated at baseline and every 6 months, up to 36 months or bDMARDs/tsDMARDs discontinuation. Patients' history, BMI, comorbidities - including osteoarthritis (OA) and fibromyalgia - were collected. Variables were compared between patients who achieved sustained MDA and those who did not. Multivariable generalized estimating equation (GEE) models were built to identify predictors of MDA and ASDAS-LDA over time. Data were expressed as beta coefficient (95%CI). RESULTS: 104 patients were enrolled, 54% males, mean age 55.7 years; 52% had axPsA. Across all evaluations, 52-61% reached MDA, and 17-24% achieved ASDAS-LDA. AxPsA, fibromyalgia, OA and BMI≥35 were less frequently observed in patients with sustained MDA. The GEE model confirmed the following factors were significantly and independently associated with MDA: age (Beta=-0.05), bDMARDs/tsDMARDs duration (Beta=+0.31), axPsA (Beta=-1.07), fibromyalgia (Beta=-3.35), OA (Beta=-1.87), BMI≥35 (Beta=-2.53). Age (Beta=-0.01), fibromyalgia (Beta=-2.03) and OA (Beta=-1.30) were also independently associated with ASDAS-LDA. CONCLUSIONS: MDA is an attainable target in real-life. AxPsA represents a difficult-to-treat subset. Sustained MDA depends on disease features (axPsA) as well as patients' characteristics (e.g. age, bDMARDs/tDMARDs duration, comorbidities).

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Ortolan A, Lorenzin M, Cozzi G, et al. Treat-to-target in real-life psoriatic arthritis patients: achieving minimal disease activity with bDMARDs/tsDMARDs and potential barriers. Semin Arthritis Rheum. 2023. PMID: 37453183. doi:10.1016/j.semarthrit.2023.152237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。